We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+124.84%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$27.8M
Cap. Flow
-$1.06M
Cap. Flow %
-0.93%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$9.22M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.54M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$746M
$49.3M 43.26%
1,954,904
+334,660
+21% +$6.54M
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$14.7M 12.94%
108,630
– –
NTRA icon
3
Natera
NTRA
$36.6B
$12.9M 11.35%
127,305
– –
KYNB
4
Kyntra Bio
KYNB
$29M
$10.6M 9.32%
12,231
– –
VRNA
5
DELISTED
Verona Pharma
VRNA
$9.29M 8.16%
+1,111,112
New +$9.22M
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$8.7M 7.64%
998,278
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$7.45M 6.55%
1,641,804
– –
NVAX icon
8
Novavax
NVAX
$1.22B
$907K 0.8%
5,000
– –

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q1 2021 Portfolio in Review

As of Q1 2021, Foresite Capital Management III held 9 positions worth $114M, up 32% from $86M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III's Q1 2021 filing shows 1 new, 1 increased and 1 closed positions. Its largest new stake was Verona Pharma: 1,111,112 shares worth $9.29M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 80% a quarter earlier.

  • Foresite Capital Management III's largest Q1 2021 buy was Verona Pharma: 1,111,112 shares worth $9.29M.
  • Foresite Capital Management III added most to Aclaris Therapeutics in Q1 2021, an estimated $6.54M increase.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $114M portfolio in Q1 2021.
  • Foresite Capital Management III opened 1 new position and closed 1 in Q1 2021.
  • Foresite Capital Management III's portfolio value rose 32% quarter-over-quarter to $114M.

Based on Foresite Capital Management III's 13F filing for Q1 2021, filed 17 May 2021.